Spots Global Cancer Trial Database for Open Label Prostate Cancer Study
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Open Label Prostate Cancer Study
Official Title: A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD3514 in Patients With Metastatic Castration-Resistant Prostate Cancer.
Study ID: NCT01162395
Conditions
Interventions
Study Description
Brief Summary: The main purpose of the study is to investigate the safety and tolerability of AZD3514 when given orally to patients with castration-resistant prostate cancer (CRPC)
Detailed Description:
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
Research Site, Portland, Oregon, United States
Research Site, Amsterdam, , Netherlands
Research Site, Glasgow, , United Kingdom
Research Site, Manchester, , United Kingdom
Research Site, Surrey, , United Kingdom
Contact Details
Name: Tony Elliott, MD
Affiliation: The Christie Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Glen Clack, MD
Affiliation: AstraZeneca
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
